Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

Jinchun Wu; Yanmin Liu; Xiaojuan Wei; Xiaofei Zhang; Yi Ye; Wei Li; Xiaoling Su

doi:10.3389/fcvm.2022.915455

Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

Front Cardiovasc Med. 2022 Aug 8:9:915455. doi: 10.3389/fcvm.2022.915455. eCollection 2022.

Authors

Jinchun Wu¹, Yanmin Liu¹, Xiaojuan Wei¹, Xiaofei Zhang¹, Yi Ye², Wei Li¹, Xiaoling Su¹

Affiliations

¹ Department of Cardiology, Qinghai Provincial People's Hospital, Xining, China.
² Graduate School of Qinghai University, Qinghai University, Xining, China.

Abstract

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.

Keywords: Ca2+ homeostasis; Na+ homeostasis; Na+-Ca2+ exchanger (NCX); Na+-H+ exchanger regulatory factor (NHERF)1/2; arrhythmia; atrial fibrillation; sodium-glucose cotransporter 2 inhibitor; ventricular arrhythmia (VAs).

Publication types

Review